Over 33,000 cancers caused by human papillomavirus (HPV)—including oropharyngeal, cervical, anal, vulvar, penile, and vaginal cancers—are diagnosed annually among men and women in the United States alone.

Federal grants from the National Institutes of Health (NIH) and the National Cancer Institute (NCI) support cancer research in every state, accelerating discoveries in prevention, early detection, treatment, and care.

Research has shown that patients with cancer and cancer survivors are at increased risk of severe illness and death if they are infected with COVID-19. In several states, AACI cancer centers are leading an effort to prioritize these vulnerable populations for the COVID-19 vaccine.